問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Digestive System Department

Division of Hematology & Oncology

Division of General Internal Medicine

MacKay Memorial Hospital

Division of General Internal Medicine

Division of Hematology & Oncology

Digestive System Department

更新時間：2023-09-19

王蒼恩
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

6Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王蒼恩

List

32Cases

2019-03-01 - 2023-12-31

Phase III

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    Cabozantinib (XL184) 20mg and 60mg tablet; Atezolizumab 1200mg/ 20ml solution for IV infusion

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites

2014-03-01 - 2015-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2016-07-01 - 2019-12-31

Phase I

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C (M7824) in subjects with metastatic or locally advanced solid tumors with expansion to selected indications in Asia

  • Condition/Disease

    metastatic or locally advanced solid tumors

  • Test Drug

    MSB0011359C (M7824)

Participate Sites
5Sites

Terminated5Sites

侯明模
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2016-05-01 - 2018-09-30

Phase III

A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro esophageal junction

  • Condition/Disease

    Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

  • Test Drug

    avelumab

Participate Sites
10Sites

Terminated9Sites

陳仁熙
Linkou Chang Gung Medical Foundation

白禮源
China Medical University Hospital-Taipei

未分科

2013-03-31 - 2019-04-30

Phase III

A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    Unresectable Hepatocellular Carcinoma

  • Test Drug

    Lenvatinib

Participate Sites
12Sites

Not yet recruiting12Sites

2008-12-01 - 2014-01-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2011-05-01 - 2013-04-30

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2007-07-02 - 2012-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2014-03-01 - 2019-01-31

Phase III

A phase III, placebo-controlled, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of K-333 (peretinoin) in patients with complete cure of hepatocellular carcinoma in Asia

  • Condition/Disease

    hepatocellular carcinoma

  • Test Drug

    K-333

Participate Sites
17Sites

Terminated16Sites

Study ended1Sites

鄭隆賓
China Medical University Hospital

2013-10-01 - 2020-07-31

Phase III

A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer

  • Condition/Disease

    Locally Advanced or Metastatic Pancreatic Cancer

  • Test Drug

    NC-6004

Participate Sites
17Sites

Terminated17Sites

蘇五洲
National Taiwan University Hospital

Division of Hematology & Oncology

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB